LL-37 — Acute Support
100 mcg twice weekly for 4 weeks — antimicrobial assist
Dose ladder
- Phase 1 / 1CycleWeeks 1–40.1 mg
What you'll need
Reference defaults for LL-37 — Acute Support. Your provider may set different values — adjust as needed.
- Vial5 mgstarting size
- BAC water2 mlfor reconstitution
- Concentration2.50 mg/mlcomputed
- Duration4+ weeks1 phase
How the app runs this for you
Auto-advance phases
LL-37 — Acute Support ramps automatically week by week — no manual tracking. The current phase and remaining weeks are visible on the home tab and the lock-screen widget.
Smart reminders
Per-protocol notifications fire at your chosen time. Missed-dose detection flags any log >15 minutes late, with one-tap resolve from the lock screen.
Body-map rotation
Each log records the injection site. The body map remembers recency so you don't reuse the same spot — especially important on multi-week protocols.
Side effects to watch for
Common in the Immune category. The iOS app lets you track all of these on a timeline and surfaces patterns as your body adapts.
- Local injection-site reaction
- Flu-like symptoms in the first dose or two
- Limited long-term safety data
Defaults
- Vial size
- 5 mg
- BAC water
- 2 ml
- Concentration
- 2.50 mg/ml
- Total weeks
- 4+
Uses LL-37. Typical dose range: 0.1–0.3 mg. Research publications. Not medical advice.
How LL-37 — Acute Support compares to other Immune protocols
2 protocols comparedQuick read of the dose ladders, durations, and concentrations across the immune category.
| Protocol | Peptide | Duration | Phases | Concentration |
|---|---|---|---|---|
| LL-37 — Acute Support | ll-37 | 4+ weeks | 1 | 2.50 mg/ml 5 mg / 2 ml |
| Thymosin Alpha-1 — Immune Support | thymosin-alpha-1 | 12+ weeks | 1 | 2.50 mg/ml 5 mg / 2 ml |
LL-37 — Acute Support FAQ
Answers, not hype.
LL-37 — Acute Support is a 4-week Immune protocol using LL-37. 100 mcg twice weekly for 4 weeks — antimicrobial assist
The standard cycle is 4+ weeks across 1 dose phase. Phase 1 (Cycle) starts at 0.1 mg per dose; the dose holds at this level for the full cycle. Individual response and provider guidance can extend or shorten the timeline.
LL-37 — Acute Support defaults to a 5 mg vial reconstituted with 2 ml of bacteriostatic water — a concentration of 2.50 mg/ml. The reconstitution calculator on this site lets you adjust to whatever vial size you actually have.
LL-37 is a research peptide and is not FDA-approved for human use. The LL-37 — Acute Support schedule reflects patterns reported in research literature, not a clinical guideline. Use only under provider supervision.
Most Immune protocols share a common side-effect pattern documented on the parent peptide page. Track them in a timeline view (the iOS app does this automatically) so you can see whether symptoms are settling at the current dose or worsening — that is the signal that determines whether to advance the next phase or hold.
No. LL-37 — Acute Support is a reference template summarizing patterns from authoritative sources. It is not a personalized treatment plan. Talk to a licensed healthcare provider before starting, modifying, or stopping any peptide protocol.
Run this protocol on autopilot
The iOS app advances this ramp week by week, fires reminders, and keeps a doctor-ready record.
Download on theApp Store